Amarin Corp Plcuk (AMRN) Assets Average (2011 - 2026)
Amarin Corp Plc\Uk (AMRN) posted quarterly Assets Average of $635.1 million for Q2 2026, down 4.2% year-over-year from $662.9 million in Q2 2025, and down 3.52% quarter-over-quarter from $658.3 million in Q1 2026.
Amarin Corp Plcuk (AMRN) Assets Average (2011 - 2026) Analysis & Trends
Amarin Corp Plc\Uk (AMRN) has reported Assets Average for 16 consecutive years, with $635.1 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Assets Average fell 4.2% year-over-year to $635.1 million; the TTM figure through Jun 2026 stood at $635.1 million (down 4.2% YoY), while the FY2025 annual figure was $678.1 million, down 10.61% from the prior year.
- Assets Average eased to $635.1 million in Q2 2026 per AMRN's latest filing, from $658.3 million in the prior quarter.
- Across five years, Assets Average topped out at $1.0 billion in Q1 2022 and bottomed at $635.1 million in Q2 2026.
- Historically, Assets Average has averaged $794.8 million across 5 years, with a median of $802.9 million in 2024.
- Annual changes were most pronounced in 2022 — Assets Average advanced 4.37% — and 2025, when it retreated 17.31%.
- Amarin Corp Plc\Uk's Assets Average stood at $897.2 million in 2022, then fell by 6.9% to $835.4 million in 2023, then declined by 14.05% to $718.0 million in 2024, then retreated by 7.34% to $665.3 million in 2025, then decreased by 4.54% to $635.1 million in 2026.
- Business Quant data shows AMRN's Assets Average at $635.1 million in Q2 2026, $658.3 million in Q1 2026, and $665.3 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 200.98 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 135.79 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 129.24 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 114.92 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 94.07 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 52.82 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 204.57 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 83.80 Bn |
| 10 | Amarin Corp Plcuk | 5.86 Bn | 5.54 Bn | 14.99 Mn | 635.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 635.10 Mn |
| Mar 31, 2026 | 658.29 Mn |
| Dec 31, 2025 | 665.29 Mn |
| Sep 30, 2025 | 664.97 Mn |
| Jun 30, 2025 | 662.91 Mn |
| Mar 31, 2025 | 670.52 Mn |
| Dec 31, 2024 | 717.98 Mn |
| Sep 30, 2024 | 775.26 Mn |
| Jun 30, 2024 | 794.96 Mn |
| Mar 31, 2024 | 810.85 Mn |
| Dec 31, 2023 | 835.36 Mn |
| Sep 30, 2023 | 849.52 Mn |
| Jun 30, 2023 | 860.11 Mn |
| Mar 31, 2023 | 873.19 Mn |
| Dec 31, 2022 | 897.24 Mn |
| Sep 30, 2022 | 940.77 Mn |
| Jun 30, 2022 | 973.47 Mn |
| Mar 31, 2022 | 1.02 Bn |
| Dec 31, 2021 | 1.05 Bn |
| Sep 30, 2021 | 1.04 Bn |